Global Cancer Vaccines Market (2018-2023) Analysis by Technology, Treatment Method, Application and Geography - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Sep 4, 2018--The “Global Cancer Vaccines Market - Segmented By Technology, Treatment Method, Application, and Geography - Growth, Trends, and Forecast (2018 - 2023)” report has been added to ResearchAndMarkets.com’s offering.
The global cancer vaccines market is expected to register a CAGR of 16% during the forecast period of 2018-2023.
The North American cancer vaccines market held the largest market share in 2017 due to the large patient pool and wide acceptance of advanced technologies.
The incidence of cancer is increasing year by year. Cancer vaccines are considered as a new therapy and are not as popular as compared to the other alternative therapeutic drugs.
However, cancer vaccines have shown great potential in both preventive and therapeutic ways. Also, with healthcare physicians looking for alternative therapies due to the huge burden of cancer cases and side effects of the present therapies, the market for cancer vaccines is expected to grow significantly during the forecast period.
The other factors, such as the emphasis on early diagnosis of cancer and technological developments in cancer vaccines are the major drivers for the market.
Notable Developments in the MarketTreos Bio Limited entered phase I trials for colon cancer. OSE Immunotherapeutics work on Tadopi, a pancreatic cancer vaccine, has entered phase III trials. Vedantra collaborated with Neon to develop cancer vaccines
Companies ProfiledAduro BioTech Inc. Amgen Astellas Pharma Inc. AstraZeneca PLC Bristol-Myers Squibb Dendreon GlaxoSmithKline Merck & Co. Inc. OSE Immunotherapeutics Sanofi Treos Bio Limited
Key Topics Covered
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Segmentation
8. Competitive Landscape
9. Key Players
10. Future of the Market
For more information about this report visit https://www.researchandmarkets.com/research/smx52z/global_cancer?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180904005469/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cancer Vaccines
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 09/04/2018 08:29 AM/DISC: 09/04/2018 08:29 AM